Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Health Care Equipment1.52%-1.02 ppPharmaceuticals4.10%+0.62 ppBiotechnology1.85%+0.08 ppLife Sciences Tools & Services0.83%-0.07 ppHealth Care Distributors0.37%-0.06 ppHealth Care Facilities0.15%-0.05 ppHealth Care Technology0.07%+0.05 ppHealth Care Services0.46%-0.03 ppManaged Health Care0.94%+0.02 ppHealth Care Supplies0.09%-0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
1.85%
Industry change · 12M
+0.08 pp
Biotechnology · contribution
+0.077 pp
Company participation
88%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Jun 2026 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| AbbVie → ABBV | United States | $444.6bn | 0.773% | +0.213 pp | +0.066 pp | +40.0% | Yes |
| Vertex Pharmaceuticals → VRTX | United States | $126.1bn | 0.219% | +0.054 pp | -0.027 pp | +11.6% | Yes |
| Moderna → MRNA | United States | $27.8bn | 0.048% | +0.019 pp | +0.025 pp | +153.8% | Yes |
| Gilead Sciences → GILD | United States | $156.9bn | 0.273% | +0.021 pp | -0.025 pp | +16.9% | Yes |
| Amgen → AMGN | United States | $195.4bn | 0.340% | +0.063 pp | +0.016 pp | +33.6% | Yes |
| Biogen → BIIB | United States | $31.9bn | 0.055% | +0.016 pp | +0.016 pp | +72.0% | Yes |
| Incyte → INCY | United States | $22.6bn | 0.039% | +0.012 pp | +0.011 pp | +66.5% | Yes |
| Regeneron Pharmaceuticals → REGN | United States | $58.6bn | 0.102% | -0.004 pp | -0.005 pp | +19.4% | No |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.